New Treatment for Donor Sites

NCT ID: NCT00591916

Last Updated: 2012-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2/PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary research questions/Purpose of the Research.

1. Determine the short term (epidermal regeneration, reduction of pain, infections and length of stay) and long term (scarring, long term recovery, and cost of treatment) outcomes of Microbial Nanocellulose (NC) and fine mesh gauze impregnated with hyaluronan and thrombin (HT).
2. Determine if donor site treatment with NC and HT is as safe as the use of Scarlet Red ointment dressing.

b. Describe the importance of the knowledge that you expect to gain from the research.

To find a donor site dressing that has outcomes equal or better than that of scarlet red.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burn

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

burn donor site grafting scar

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.

Group Type EXPERIMENTAL

Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]

Intervention Type DRUG

Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

Blood sample

Intervention Type PROCEDURE

Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

Biopsy

Intervention Type PROCEDURE

Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.

2

fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.

Group Type EXPERIMENTAL

Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]

Intervention Type DRUG

Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

Blood sample

Intervention Type PROCEDURE

Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

Biopsy

Intervention Type PROCEDURE

Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.

3

Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.

Group Type ACTIVE_COMPARATOR

Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]

Intervention Type DRUG

Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

Blood sample

Intervention Type PROCEDURE

Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

Biopsy

Intervention Type PROCEDURE

Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]

Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

Intervention Type DRUG

Blood sample

Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

Intervention Type PROCEDURE

Biopsy

Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 0-90 years.
* Any patient admitted to the hospital with burn injury requiring grafting and a donor site.

Exclusion Criteria

* Patient with severe burn injuries expected to die.
Minimum Eligible Age

1 Day

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Texas Medical Branch, Galveston

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David N Herndon, MD

Role: PRINCIPAL_INVESTIGATOR

University of Texas

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06-388

Identifier Type: -

Identifier Source: org_study_id